- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Joint agreement promotes film and CAD
Kodak and R2 Technologies have entered into a joint marketing agreement to bundle each other’s products—Kodak’s MIN-R 2000 mammography screen-film system and R2’s ImageChecker system—for sale to Novation and the University
Kodak and R2 Technologies have entered into a joint marketing agreement to bundle each other’s products-Kodak’s MIN-R 2000 mammography screen-film system and R2’s ImageChecker system-for sale to Novation and the University HealthSystem Consortium. Kodak and R2 each already has a sole source agreement with the two group purchasing organizations. ImageChecker is a computer-aided detection system designed to digitize, analyze, and flag suspicious areas on mammograms. The Kodak MIN-R 2000 yields greater resolution, more detail, and higher contrast than any other Kodak mammography screen-film system. The joint agreement is designed to enable Voluntary Hospital Association and UHC members to easily avail themselves of Kodak’s and R2’s products. Novation is the supply company for VHA; UHC represents more than 2300 healthcare organizations.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
